SWP
TCRT icon

Stratos Wealth Partners’s Alaunos Therapeutics TCRT Stock Holding History

Stratos Wealth Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-92
Closed -$102K – 664
2016
Q1 		$102K Buy
+92
New +$94.2K 0.01% 550

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stratos Wealth Partners's TCRT Position: Q2 2016 in Review

Stratos Wealth Partners sold out of Alaunos Therapeutics (TCRT) in Q2 2016, closing a stake of 92 shares — an estimated $102K sold.

Stratos Wealth Partners first reported a position in TCRT in Q1 2016 and held it in 1 quarter. The position peaked at $102K in Q1 2016. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • Stratos Wealth Partners reported no remaining Alaunos Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Stratos Wealth Partners sold 92 Alaunos Therapeutics shares in Q2 2016, an estimated $102K.
  • Stratos Wealth Partners first reported a position in Alaunos Therapeutics in Q1 2016 and held it in 1 quarter.
  • Stratos Wealth Partners's Alaunos Therapeutics position peaked at $102K in Q1 2016.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on Stratos Wealth Partners's 13F filing for Q2 2016, filed 12 Aug 2016.